Niflumic acid


Concise Prescribing Info
Indications/Uses
Pain and inflammation associated w/ musculoskeletal and joint disorders.
Dosage/Direction for Use
Adult: PO 250 mg 3-4 times/day. Max: 1.5 g/day. Topical As 3% cream/oint or 2.5% gel: Apply as directed.
Administration
Should be taken with food. Take w/ or immediately after meals.
Contraindications
Active peptic ulceration, severe heart failure.
Special Precautions
Discontinue if hypersensitivity skin reactions occur. Pregnancy, lactation. Elderly, patients with haemorrhagic disorders; hypertension; impaired renal, hepatic, cardiac function; asthma; infections; left ventricular failure; oedema; history of CHF.
Adverse Reactions
CNS disturbances, hypersensitivity reactions, renal/hepatic disorders, GI disturbances, cutaneous reactions, agranulocytosis, neutropenia. Fluid retention, photosensitivity, alveolitis, pulmonary eosinophilia, pancreatitis, Stevens-Johnson syndrome, exacerbation of colitis.
Drug Interactions
May increase concentration of methotrexate, cardiac glycosides. Increased risk of nephrotoxicity with ACE inhibitors, ciclosporin, tacrolimus, diuretics. Increased risk of GI bleeding with corticosteroids, SSRIs, venlafaxine, clopidogrel, ticlopidine, iloprost, erlotinib, sibutramine, alcohol, bisphosphonates, pentoxifylline.
ATC Classification
M02AA17 - niflumic acid ; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.
M01AX02 - niflumic acid ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by CIMS based on niflumic acid from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in